EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the first four patients have been dosed in a Phase 1/2a study using the Company’s...
Cerveau Technologies Inc.,today announced a research collaboration with the LuMind IDSC Foundation (LuMind IDSC) involving use of Cerveau’s investigational imaging agent (MK-6240) in a multicenter clinical trial aimed at assessing accumulation of misfolded tau protein...
A new therapy to re-engage the heart’s natural electrical pathways – instead of bypassing them – could mean more treatment options for heart failure patients who also suffer from electrical disturbances, such as arrhythmias, according to research led by the University...
LATITUDE study compares monthly injectable antiretroviral therapy to daily oral drugs A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge...
Plain language trial summary template for patients will be available to all members in the National Cancer Institute’s National Clinical Trials Network. With financial support from The Hope Foundation for Cancer Research, a team of patient advocates and communications...
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today...
Email
Text